Valvular Heart Disease: Replacement and Repair


Key Points

  • 1.

    Although various valvular lesions generate different physiologic changes, all valvular heart disease is characterized by abnormalities of ventricular loading.

  • 2.

    The left ventricle normally compensates for increases in afterload by increases in preload. This increase in end-diastolic fiber stretch or radius further increases wall tension in accordance with Laplace's law, resulting in a reciprocal decline in myocardial fiber shortening. The stroke volume is maintained because the contractile force is augmented at the higher preload level.

  • 3.

    Treatment modalities for hypertrophic obstructive cardiomyopathy, a relatively common genetic malformation of the heart, include β-adrenoceptor antagonists, calcium channel blockers, and myectomy of the septum. Newer approaches include dual-chamber pacing and septal reduction (ie, ablation) therapy with ethanol.

  • 4.

    The severity and duration of symptoms of aortic regurgitation may correlate poorly with the degree of hemodynamic and contractile impairment, delaying surgical treatment while patients are undergoing progressive deterioration.

  • 5.

    Mitral regurgitation causes left ventricular volume overload. Treatment depends on the underlying mechanism and includes early reperfusion therapy, angiotensin-converting enzyme inhibitors, and surgical repair or replacement of the mitral valve.

  • 6.

    Rheumatic disease and congenital abnormalities of the mitral valve are the main causes of mitral stenosis, a slowly progressive disease. Surgical treatment options include closed and open commissurotomy and percutaneous mitral commissurotomy.

  • 7.

    Most tricuspid surgery occurs in the context of significant aortic or mitral disease, and anesthesia management primarily is determined by the left-sided valve lesion.

  • 8.

    Innovations in surgical valve repair include aortic valve repair and closed- and open-chamber procedures for mitral regurgitation.

Valve surgery is very different from coronary artery bypass grafting (CABG). Over the natural history of valvular heart disease (VHD), the physiology changes markedly. In the operating room, physiologic conditions and hemodynamics are quite dynamic and are readily influenced by anesthesia. For some types of valve lesions, it can be relatively difficult to predict before surgery how the heart will respond to the altered loading conditions associated with valve repair or replacement.

It is essential to understand the natural history of adult-acquired valve defects and how the pathophysiology evolves. Clinicians must also understand surgical decision making for valve repair or replacement. A valve operated on at the appropriate stage of its natural history has a good and more predictable outcome compared with a heart operated on at a later stage, for which the perioperative result can be poor. The dynamic physiology and natural history of each valve defect govern the anesthesia plan, which must include the requirements for preload, pacing rate, and rhythm; use of inotropes or negative inotropes; and use of vasodilators or vasoconstrictors to alter loading conditions.

Although valvular lesions impose different physiologic changes, a unifying concept is that all VHD is characterized by abnormalities of ventricular loading. The status of the ventricle changes over time because ventricular function and the valvular defect itself are influenced by the progression of volume or pressure overload. The clinical status of patients with VHD can be complex and dynamic. It is possible to have clinical decompensation in the context of normal ventricular contractility or have ventricular decompensation and performance with normal ejection indices. The altered loading conditions characteristic of VHD may result in a divergence between the function of the heart as a systolic pump and the intrinsic inotropic state of the myocardium. The divergence between cardiac performance and inotropy results from compensatory physiologic mechanisms that are specific to each of the ventricular loading abnormalities.

Aortic Stenosis

Clinical Features and Natural History

Aortic stenosis (AS) is the most common cardiac valve lesion in the United States. Approximately 1% to 2% of people are born with a bicuspid aortic valve, which is prone to stenosis with aging. Clinically significant aortic valve stenosis occurs in 2% of unselected individuals older than 65 years and in 5.5% of those older than 85 years.

Calcific AS has several features in common with coronary artery disease (CAD). Both conditions are more common in men, older people, and patients with hypercholesterolemia, and both result in part from an active inflammatory process. Clinical evidence indicates that an atherosclerotic process is the cellular mechanism of aortic valve stenosis. There is a clear association between clinical risk factors for atherosclerosis and the development of AS: increased lipoprotein levels, increased low-density lipoprotein (LDL) cholesterol, cigarette smoking, hypertension, diabetes mellitus, increased serum calcium and creatinine levels, and male sex. The early lesion of aortic valve sclerosis may be associated with CAD and vascular atherosclerosis. Aortic valve calcification is an inflammatory process promoted by atherosclerotic risk factors.

The average rate of progression is a decrease in aortic valve area (AVA) of 0.1 cm 2 /year, and the peak instantaneous gradient increases by 10 mm Hg/year. The rate of progression of AS in men older than 60 is faster than in women, and it is faster in women older than 75 than in women 60 to 74 years old.

Angina, syncope, and congestive heart failure (CHF) are the classic symptoms of the disease, and their appearance is of serious prognostic significance because postmortem studies indicate that symptomatic AS is associated with a life expectancy of only 2 to 5 years.

There is evidence that patients with moderate AS (ie, valve areas of 0.7 to 1.2 cm 2 ) are also at increased risk for complications, with the appearance of symptoms further increasing their risk.

Angina is a frequent and classic symptom of the disease, occurring in approximately two-thirds of patients with critical AS, and about one-half of symptomatic patients have anatomically significant CAD.

It is probably never too late to operate on patients with symptomatic AS. Unlike patients with aortic regurgitation (AR), most symptomatic patients undergo valve replacement when left ventricular function is still normal. Even when impaired left ventricular function develops in AS, the relief of pressure overload almost always restores normal function or produces considerable improvement. Morbidity rates, mortality rates, and clinical results are favorable even for the oldest surgical candidates. Advances in operative techniques and perioperative management have contributed to excellent results after aortic valve replacement (AVR) in patients 80 years of age or older, with minimal incremental postoperative morbidity.

Preoperative assessment of AS with Doppler echocardiography includes measurement of the AVA and the transvalvular pressure gradient. The latter is calculated from the Doppler-quantified transvalvular velocity of blood flow, which is increased in the setting of AS. The maximal velocity (v) is then inserted into the modified Bernoulli equation to determine the pressure gradient (PG) between the left ventricle (LV) and the aorta:


PG = P ( left ventricle ) P ( aorta ) = 4 ( v 2 )

The pressure gradient is the maximal difference between the LV and aortic pressures that occurs during ventricular systole.

Pressure gradients determined invasively or by Doppler echocardiography correctly classify AS severity in less than 50% of cases compared with estimates of AVA. The preferred method of obtaining AVA requires only two Doppler-generated velocities: those proximal or distal to the stenotic valve. These values are inserted into the continuity equation, which relates the respective velocities and cross-sectional areas proximal and distal to a stenotic area:


V max × AVA = area ( LVOT ) × V ( LVOT )

In the equation, AVA is the aortic valve area, V is the volume, and LVOT is the left ventricular outflow tract.

Pathophysiology

The normal AVA is 2.6 to 3.5 cm 2 , with hemodynamically significant obstruction usually occurring at cross-sectional valve areas of 1 cm 2 or less. Accepted criteria for critical outflow obstruction include a systolic pressure gradient greater than 50 mm Hg, with a normal cardiac output, and an AVA of less than 0.4 cm 2 . In view of the ominous natural history of severe AS (AVA <0.7 cm 2 ), symptomatic patients with this degree of AS are usually referred for immediate AVR. A simplification of the Gorlin equation to calculate the AVA is based on the cardiac output (CO) and the peak pressure gradient (PG) across the valve.


AVA = CO / ( PG )

An obvious corollary of the previously described relationship is that “minimal” pressure gradients may reflect critical degrees of outflow obstruction when the CO is significantly reduced (ie, generation of a pressure gradient requires some finite amount of flow). Clinicians have long recognized this phenomenon as a paradoxical decline in the intensity of the murmur (ie, minimal transvalvular flow) as the AS worsens.

Stenosis at the level of the aortic valve results in a pressure gradient from the LV to the aorta. The intracavitary systolic pressure generated to overcome this stenosis directly increases myocardial wall tension in accordance with Laplace's law:


Wall tension = P × R / 2 h

In the equation, P is the intraventricular pressure, R is the inner radius, and h is the wall thickness.

The increase of wall tension is thought to be the direct stimulus for the further parallel replication of sarcomeres, which produces the concentrically hypertrophied ventricle characteristic of chronic pressure overload. The consequences of left ventricular hypertrophy (LVH) include alterations in diastolic compliance, potential imbalances in the myocardial oxygen supply and demand relationship, and possible deterioration of the intrinsic contractile performance of the myocardium.

Fig. 15.1 shows a typical pressure-volume loop for a patient with AS. Two differences from the normal curve are immediately apparent. First, the peak pressure generated during systole is much greater because of the high transvalvular pressure gradient. Second, the slope of the diastolic limb is steeper, reflecting the reduced left ventricular diastolic compliance that is associated with the increase in chamber thickness. Clinically, small changes in diastolic volume produce relatively large increases in ventricular filling pressure.

Fig. 15.1, Simultaneous left ventricular (LV) volume and pressure during one cardiac cycle. ECG, Electrocardiogram.

Increased chamber stiffness places a premium on the contribution of atrial systole to ventricular filling, which in patients with AS may account for up to 40% of the left ventricular end-diastolic volume (LVEDV) rather than the 15% to 20% characteristic of the normal LV. Echocardiographic and radionuclide studies have documented that diastolic filling and ventricular relaxation are abnormal in patients with hypertrophy from a variety of causes, and significant prolongation of the isovolumic relaxation period is the most characteristic finding. This necessarily compromises the duration and amount of filling achieved during the early rapid diastolic filling phase and increases the relative contribution of atrial contraction to overall diastolic filling. A much greater mean left atrial pressure is necessary to distend the LV in the absence of the sinus mechanism. One treatment of junctional rhythm is volume infusion.

The systolic limb of the pressure-volume loop shows preservation of pump function, as evidenced by maintenance of the stroke volume (SV) and ejection fraction (EF). Use of preload reserve and adequate LVH are likely the principal compensatory mechanisms that maintain forward flow. Clinical studies have confirmed that ejection performance is preserved at the expense of myocardial hypertrophy, and the adequacy of the hypertrophic response has been related to the degree to which it achieves normalization of wall stress, in accordance with the Laplace relation. LVH can be viewed as a compensatory physiologic response; however, severe afterload stress and proportionately massive LVH could decrease subendocardial perfusion and superimpose a component of ischemic contractile dysfunction.

In AS, signs and symptoms of CHF usually develop when preload reserve is exhausted, not because contractility is intrinsically or permanently impaired. This contrasts with mitral regurgitation (MR) and AR, in which irreversible myocardial dysfunction may develop before the onset of significant symptoms.

The major threat to the hypertrophied ventricle is its exquisite sensitivity to ischemia. Ventricular hypertrophy directly increases basal myocardial oxygen demand (MV̇ o 2 ). The other major determinants of overall MV̇ o 2 are heart rate, contractility, and, most important, wall tension. Increases in wall tension occur as a direct consequence of Laplace's law in patients with relatively inadequate hypertrophy. The possibility of ischemic contractile dysfunction in the inadequately hypertrophied ventricle arises from increases in wall tension, which directly parallels the imbalance between the increased peak systolic pressure and the degree of mural hypertrophy. Although there is considerable evidence for supply-side abnormalities in the myocardial supply and demand relationship in patients with AS, clinical data also support increased MV̇ o 2 as important in the genesis of myocardial ischemia.

On the supply side, the greater left ventricular end-diastolic pressure (LVEDP) of the poorly compliant ventricle inevitably narrows the diastolic coronary perfusion pressure (CPP) gradient. With severe outflow obstruction, decreases in SV and resultant systemic hypotension may critically compromise coronary perfusion. A vicious cycle may develop because ischemia-induced abnormalities of diastolic relaxation can aggravate the compliance problem and further narrow the CPP gradient. This sets the stage for ischemic contractile dysfunction, additional decreases in SV, and worsening hypotension.

Difficulty of Low-Gradient, Low-Output Aortic Stenosis

A subset of patients with severe AS, left ventricular dysfunction, and low transvalvular gradient suffers a high operative mortality rate and poor prognosis. It is difficult to assess accurately the AVA in low-flow, low-gradient AS because the calculated valve area is proportional to forward SV and because the Gorlin constant varies in low-flow states. Some patients with low-flow, low-gradient AS have a decreased AVA as a result of inadequate forward SV rather than anatomic stenosis. Surgical therapy is unlikely to benefit these patients because the underlying pathology is a weakly contractile myocardium. However, patients with severe anatomic AS may benefit from valve replacement despite the increased operative risk associated with the low-flow, low-gradient hemodynamic state. American College of Cardiology/American Heart Association (ACC/AHA) guidelines call for a dobutamine echocardiography evaluation to differentiate patients with fixed anatomic AS from those with flow-dependent AS with left ventricular dysfunction. Low-flow, low-gradient AS is defined as a mean gradient of less than 30 mm Hg and a calculated AVA less than 1.0 cm 2 .

Timing of Intervention

For asymptomatic patients with AS, it appears to be relatively safe to delay surgery until symptoms develop, but outcomes vary widely. Moderate or severe valvular calcification along with a rapid increase in aortic-jet velocity identify patients with a very poor prognosis. They should be considered for early valve replacement rather than delaying until symptoms develop.

Echocardiography and exercise testing may identify asymptomatic patients who are likely to benefit from surgery. In a study of 58 asymptomatic patients, 21 had symptoms for the first time during exercise testing. Guidelines for AVR in patients with AS are shown in Table 15.1 .

Table 15.1
Pressure-Overload Hypertrophy
From Lorell BH, Grossman W. Cardiac hypertrophy: the consequences for diastole. J Am Coll Cardiol. 1987;9:1189.
Beneficial Aspects Detrimental Aspects
Increases ventricular work Decreases ventricular diastolic distensibility
Normalizes wall stress Impairs ventricular relaxation
Normalizes systolic shortening Impairs coronary vasodilator reserve, leading to subendocardial ischemia

Functional outcome after AVR for patients older than 80 years is excellent, operative risk is limited, and late survival rates are good. For patients with severe left ventricular dysfunction and a low transvalvular mean gradient, the operative mortality rate was increased, but AVR was associated with improved functional status. Postoperative survival rates were best for younger patients and those with larger prosthetic valves, whereas medium-term survival rates were correlated with improved postoperative functional class.

Anesthesia Considerations

The described pathophysiologic principles dictate anesthesia management based on avoidance of systemic hypotension, maintenance of sinus rhythm and an adequate intravascular volume, and awareness of the potential for myocardial ischemia ( Box 15.1 ). In the absence of CHF, adequate premedication may reduce the likelihood of undue preoperative excitement, tachycardia, and exacerbation of myocardial ischemia and the transvalvular pressure gradient. In patients with critical outflow tract obstruction, however, heavy premedication with an exaggerated venodilatory response can reduce the appropriately increased LVEDV (and LVEDP) needed to overcome the systolic pressure gradient. In these patients, the additional precaution of administering supplementary oxygen may obviate the possibility of a similarly pronounced response to the sedative effects of the premedicant.

Box 15.1
Aortic Stenosis

  • Maintain preload and diastolic filling

  • Maintain sinus rhythm

  • Maintain or increase afterload

  • Avoid myocardial depression

  • Avoid tachycardia, hypotension, and increased myocardial oxygen demand situations

Intraoperative monitoring should include a standard five-lead electrocardiographic (ECG) system, including a V 5 lead, because of the LV's vulnerability to ischemia. A practical constraint in terms of interpretation is that these patients usually exhibit ECG changes because of preoperative LVH. The associated ST-segment abnormalities (ie, strain pattern) may be indistinguishable from or very similar to those of myocardial ischemia, making the intraoperative interpretation difficult. Lead II and possibly an esophageal electrocardiogram should be readily obtainable for assessing the P-wave changes in the event of supraventricular arrhythmias.

Hemodynamic monitoring is controversial, and few prospective data are available on which to base an enlightened clinical decision. The central venous pressure (CVP) is a particularly poor estimate of left ventricular filling when left ventricular compliance is reduced. A normal CVP can significantly underestimate the LVEDP or pulmonary capillary wedge pressure (PCWP). The principal risks, although minimal, of using a pulmonary artery catheter (PAC) in the patient with AS are arrhythmia-induced hypotension and ischemia. Loss of synchronous atrial contraction or a supraventricular tachyarrhythmia can compromise diastolic filling of the poorly compliant LV, resulting in hypotension and the potential for rapid hemodynamic deterioration. The threat of catheter-induced arrhythmias is significant for the patient with AS. However, accepting a low-normal CVP as evidence of good ventricular function can lead to similarly catastrophic underfilling of the LV on the basis of insufficient replenishment of surgical blood loss. To some extent, even the PCWP can underestimate the LVEDP (and LVEDV) when ventricular compliance is markedly reduced. Placement of a PAC also allows measurement of CO, derived hemodynamic parameters, mixed venous oxygen saturation (Sv o 2 ), and possible transvenous pacing.

Intraoperative fluid management should be aimed at maintaining appropriately increased left-sided filling pressures. This is one reason why many clinicians think that the PAC is worth its small arrhythmogenic risk. Keeping up with intravascular volume losses is particularly important in noncardiac surgery, in which the shorter duration of the operation may make inhalation or potentially vasodilating regional anesthesia preferable to a narcotic technique.

Patients with symptomatic AS are usually encountered only in the setting of cardiovascular surgery because of their ominous prognosis without AVR. Few studies have specifically addressed the response of these patients to the standard intravenous and inhalation induction agents; however, the responses to narcotic and nonnarcotic intravenous agents are apparently not dissimilar from those of patients with other forms of VHD. The principal benefit of a narcotic induction is assurance of an adequate depth of anesthesia during intubation, which reliably blunts potentially deleterious reflex sympathetic responses capable of precipitating tachycardia and ischemia.

Many clinicians also prefer a pure narcotic technique for maintenance. The negative inotropy of inhalation anesthetics is a theoretical disadvantage for a myocardium faced with the challenge of overcoming outflow tract obstruction. A more clinically relevant drawback may be the increased risk for arrhythmia-induced hypotension, particularly that associated with nodal rhythm and resultant loss of the atrium's critical contribution to filling of the hypertrophied ventricle.

Occasionally, surgical stimulation elicits a hypertensive response despite the impedance posed by the stenotic valve and a seemingly adequate depth of narcotic anesthesia. In these patients, a judicious trial of low concentrations of an inhalation agent, used purely for control of hypertension, may prove efficacious. The ability to concurrently monitor CO is useful in this situation. The temptation to control intraoperative hypertension with vasodilators should be resisted in most cases. Given the risk for ischemia, nitroglycerin seems to be a particularly attractive drug. Its effectiveness in relieving subendocardial ischemia in patients with AS is controversial; however, there is always the risk for transient episodes of overshoot. The hypertrophied ventricle's critical dependence on an adequate CPP may be unforgiving of even a momentary dip in the systemic arterial pressure.

Intraoperative hypotension, regardless of the primary cause, should be treated immediately and aggressively with a direct α-adrenergic agonist such as phenylephrine. The goal should be to immediately restore the CPP and then to address the underlying problem (eg, hypovolemia, arrhythmia). After the arterial pressure responds, treatment of the precipitating event should be equally aggressive, but rapid transfusion or cardioversion should not delay the administration of a direct-acting vasoconstrictor. Patients with severe AS in whom objective signs of myocardial ischemia persist despite restoration of the blood pressure should be treated extremely aggressively. This may mean the immediate use of an inotropic agent or accelerating the institution of cardiopulmonary bypass (CPB).

Hypertrophic Cardiomyopathy

Hypertrophic Obstructive Cardiomyopathy

Obstructive hypertrophic cardiomyopathy (HCM) is a relatively common genetic malformation of the heart with a prevalence of approximately 1 case in 500 births. The hypertrophy initially develops in the septum and extends to the free walls, often giving a picture of concentric hypertrophy. Asymmetric septal hypertrophy leads to a variable pressure gradient between the apical left ventricular chamber and the LVOT. The LVOT obstruction leads to increases in left ventricular pressure, which fuels a vicious cycle of further hypertrophy and increased LVOT obstruction.

Treatment modalities include β-adrenoceptor antagonists, calcium channel blockers, and surgical myectomy of the septum. For more than 40 years, the standard treatment has been the ventricular septal myotomy-myectomy of Morrow, in which a small amount of muscle from the subaortic septum is resected. Two new treatment modalities have gained popularity in recent years: dual-chamber pacing and septal reduction (ie, ablation) with ethanol.

Clinical Features and Natural History

The clinical presentation of patients varies widely. Echocardiography has unquestionably increased the number of asymptomatic patients who carry the diagnosis. Most patients with HCM are asymptomatic and have been seen by the echocardiographer because of relatives having clinical disease. Follow-up remains an important problem for cardiologists because sudden death or cardiac arrest may occur as the presenting symptom in slightly more than one-half of previously asymptomatic patients.

Less dramatic presenting complaints include dyspnea, angina, and syncope. The clinical picture is often similar to valvular AS. The symptoms may share a similar pathophysiologic basis (eg, poor diastolic compliance) in the two conditions. The prognostic implications of clinical disease, however, are less certain for patients with HCM. Although cardiac arrest may be an unheralded event, some patients may have a stable pattern of angina or intermittent syncopal episodes for many years. Palpitations are frequently described and may be related to a variety of underlying arrhythmias.

Pathophysiology

In HCM, the principal pathophysiologic abnormality is myocardial hypertrophy. The hypertrophy is a primary event in these patients and occurs independently of outflow tract obstruction. Unlike in AS, the hypertrophy begets the pressure gradient, not the other way around. Histologically, the hypertrophy consists of myocardial fiber disarray, and anatomically, there is usually disproportionate enlargement of the interventricular septum.

HCM is characterized by a broad spectrum of obstruction, which is absent in some patients and varies from mild to severe in others. The most distinctive qualities of obstruction are its dynamic nature (ie, depends on contractile state and loading conditions), its timing (ie, begins early and peaks variably), and its subaortic location. Subaortic obstruction arises from the hypertrophied septum's encroachment on the systolic outflow tract, which is bounded anteriorly by the interventricular septum and posteriorly by the anterior leaflet of the mitral valve. In most patients with obstruction, exaggerated anterior (ie, toward the septum) motion of the anterior mitral valve leaflet during systole accentuates the obstruction. The cause of systolic anterior motion (SAM) is unclear. One possibility is that the mitral valve is pulled toward the septum by contraction of the papillary muscles, whose orientation is abnormal because of the hypertrophic process. Another theory is that vigorous contraction of the hypertrophied septum results in rapid acceleration of the blood through a simultaneously narrowed outflow tract. The generated hydraulic forces (consistent with a Venturi effect) can cause the anterior leaflet of the mitral valve to be drawn close to or in contact with the interventricular septum ( Fig. 15.2 ). After the obstruction is triggered, the mitral valve leaflet is forced against the septum by the pressure difference across the orifice. However, the pressure difference further decreases orifice size and further increases the pressure difference in a time-dependent, amplifying feedback loop. This analysis is consistent with observations that the measured gradient directly correlates with the duration of mitral-septal contact. Although still controversial, there appears to be good correlation between the degree of SAM and the magnitude of the pressure gradient. The SAM-septal contact also underlies the severe subaortic obstruction characteristic of HCM of the elderly, although the narrowing usually is more severe and the contribution of septal movement toward the mitral valve is usually greater.

Fig. 15.2, Proposed mechanism of systolic anterior motion in hypertrophic cardiomyopathy. (A) Normally, blood is ejected from the left ventricle (LV) through an unimpeded outflow tract. (B) Thickening of the ventricular septum restricts the outflow tract, and the obstruction causes the blood to be ejected at a higher velocity and closer to the area of the anterior mitral valve (MV) leaflet. Owing to its proximity to the high-velocity fluid path, the anterior MV leaflet is drawn toward the hypertrophied septum by a Venturi effect (left arrow) .

In addition to SAM, approximately two-thirds of patients exhibit a constellation of structural malformations of the mitral valve. Malformations include increased leaflet area and elongation of the leaflets or anomalous papillary muscle insertion directly into the anterior mitral valve leaflet. HCM is not a disease process confined to cardiac muscle alone because these anatomic abnormalities of the mitral valve are unlikely to be acquired or caused by mechanical factors.

Three basic mechanisms—increased contractility, decreased afterload, and decreased preload—exacerbate the degree of SAM-septal contact and produce the dynamic obstruction characteristic of patients with HCM. The common pathway is a reduction in ventricular volume (actively by increased contractility directly or reflexively in response to vasodilation or passively by reduced preload), which increases the proximity of the anterior mitral valve leaflet to the hypertrophied septum. Factors that usually impair contractile performance, such as myocardial depression, systemic vasoconstriction, and ventricular overdistension, characteristically improve systolic function in patients with HCM and outflow tract obstruction.

Diagnostically, the paradoxes are exploited by quantifying the degree of subaortic obstruction after isoproterenol (eg, increased inotropy, tachycardia, decreased volume) and the Valsalva maneuver (eg, decreased venous return, ventricular volume), both of which reliably elicit increases in the pressure gradient. In the operating room, catheter-induced ectopy or premature ventricular contractions resulting from cardiac manipulation may transiently exacerbate the gradient by increased inotropy from postextrasystolic potentiation. Therapeutically, volume loading, myocardial depression, and vasoconstriction can minimize obstruction and augment forward flow.

Poor diastolic compliance is the most clinically apparent manifestation of the relaxation abnormalities. Left ventricular filling pressures are markedly increased despite enhanced systolic ejection and a normal or subnormal EDV. The reduced ventricular volume emphasizes the pivotal role played by the hypertrophied but intrinsically depressed myocardium. Reductions in afterload, which are mediated by hypertrophy, support the ventricle's systolic performance, resulting in increased emptying and a small diastolic volume. However, hypertrophy also impairs relaxation, resulting in poor diastolic compliance and an increased ventricular filling pressure. The high filling pressure does not reflect distension of a failing ventricle, although stress-volume relationships suggest that contractility is intrinsically depressed. This disease is characterized by systolic and diastolic dysfunction.

As in patients with valvular AS, relatively high filling pressures reflect the LVEDV (ie, degree of preload reserve) needed to overcome the outflow obstruction. Intervention with vasodilators is therefore inappropriate. The poor ventricular compliance also means that patients with HCM depend on a large intravascular volume and the maintenance of sinus rhythm for adequate diastolic filling. The atrial contribution to ventricular filling is even more important in HCM than in valvular AS, and it may approach 75% of total SV.

Another similarity between HCM and valvular AS is that the combination of myocardial hypertrophy, with or without LVOT obstruction, may precipitate imbalances in the myocardial oxygen supply and demand relationship. Angina-like discomfort is a classic symptom of patients with HCM, and its pathogenesis has been attributed to increases in MV̇ o 2 , specifically the increased overall muscle mass and the high systolic wall tension generated by the ventricle's ejection against the dynamic subaortic obstruction. However, as in patients with AS, there is evidence of a compromise in myocardial oxygen supply.

β-Blockers and calcium channel blockers form the basis of medical therapy for HCM. β-Blockade is most useful for preventing sympathetically mediated increases in the subaortic gradient and for the prevention of tachyarrhythmias, which can exacerbate outflow obstruction. Disopyramide also has been used to reduce contractility and for its antiarrhythmic properties. Calcium channel blockers often prove clinically effective in patients with HCM, regardless of the presence or absence of systolic obstruction. The mechanism of action involves improvement in diastolic relaxation, allowing an increase in LVEDV at a lower LVEDP. The negative inotropy may attenuate the subaortic pressure gradient, but in selected patients the gradient may worsen because of pronounced and unpredictable degrees of vasodilation.

Surgery (ie, septal myotomy or partial myomectomy by the aortic approach) is reserved for patients who remain symptomatic despite maximal pharmacologic therapy. In a long-term retrospective study, the cumulative survival rate was significantly better in surgically than in pharmacologically treated patients. However, it is likely that pharmacologic therapy may be more appropriate for the patient with a dynamic component to their degree of subaortic obstruction. Further improvement in the clinical outcome of surgically treated patients may be achieved with the addition of verapamil, presumably reflecting a two-pronged attack on the systolic (ie, myomectomy) and diastolic (ie, verapamil) components of the disease. Enthusiasm continues for the therapeutic use of dual-chamber pacing in this disease, with some patients demonstrating reductions in their subaortic gradients. It is not an option for patients with atrial fibrillation (AF).

Anesthesia Considerations

Priorities in anesthesia management are to avoid aggravating the subaortic obstruction while remaining aware of the derangements in diastolic function that may be somewhat less amenable to direct pharmacologic manipulation ( Box 15.2 ). It is necessary to maintain an appropriate intravascular volume while avoiding direct or reflex increases in contractility or heart rate. The latter goals can be achieved with a deep level of general anesthesia and the associated direct myocardial depression. Regardless of the specific technique, preservation of an adequate CPP using vasoconstrictors rather than inotropes is necessary to avoid myocardial ischemia. Heavy premedication is advisable, with a view to avoiding anxiety-induced tachycardia or a reduction in ventricular filling. Chronic β-blockade or calcium channel blockade, or both, should be continued up to and including the day of surgery. These medications should be restarted immediately after surgery, particularly in patients undergoing noncardiac surgery.

Box 15.2
Hypertrophic Cardiomyopathy

  • Preload is increased

  • Afterload is increased

  • Goal is myocardial depression

  • Avoid tachycardia, inotropes, and vasodilators

Intraoperative monitoring should include an ECG system with the capability of monitoring a V 5 lead and each of the six limb leads. Inspection of lead II may be helpful in the accurate diagnosis of supraventricular and junctional tachyarrhythmias, which may precipitate catastrophic hemodynamic deterioration because of the potential for inadequate ventricular filling resulting from the reduction in diastolic time or loss of the atrial contribution to ventricular filling. The latter may be crucial in patients with significantly reduced diastolic compliance. Abnormal Q waves have been described on the electrocardiograms of 20% to 50% of patients with HCM. These waves should not raise concern about a previous myocardial infarction; instead, they probably represent accentuation of normal septal depolarization or delay in depolarization of electrophysiologically abnormal cells. Some patients exhibit a short PR interval with initial slurring of the QRS complex, and they may be at increased risk for supraventricular tachyarrhythmias due to preexcitation. Although the specific predisposing factors are unknown, patients with HCM are at increased risk for any type of arrhythmia in the operative setting.

Given the pronounced abnormalities in left ventricular diastolic compliance, the CVP is likely to be an inaccurate guide to changes in left ventricular volume. However, a CVP catheter is extremely useful for the prompt administration of vasoactive drugs if they become necessary. As in valvular AS, the information provided by insertion of a PAC is worth the small arrhythmogenic risk. The potential for hypovolemia-induced exacerbation of outflow tract obstruction makes it crucial that the clinician have an accurate gauge of intravascular filling. Reduced diastolic compliance means that the PCWP overestimates the patient's true volume status, and a reasonable clinical objective is to maintain the PCWP in the high-normal to elevated range. A PAC with pacing capability is ideal because atrial overdrive pacing can effect immediate hemodynamic improvement in the event of episodes of junctional rhythm. The absolute requirement of these patients for an adequate preload cannot be overemphasized because even abrupt positioning changes have resulted in acute hemodynamic deterioration, including acute pulmonary edema.

Intraoperative arrhythmias require aggressive therapy. During cardiac surgery, insertion of venous cannulas may precipitate atrial arrhythmias. Because the resultant hypotension may be severe, the surgeon should cannulate the aorta before atrial manipulation. Supraventricular or junctional tachyarrhythmias may require immediate cardioversion if they precipitate catastrophic degrees of hypotension. Although verapamil is one drug of choice for paroxysmal atrial and junctional tachycardia, it can disastrously worsen the LVOT obstruction if it elicits excessive vasodilation or it is used in the setting of severe hypotension. Cardioversion is preferable when the mean arterial pressure is already very low. The concurrent administration of phenylephrine also is advisable. This drug is typically a low-risk, high-yield choice for the hypotensive patient with HCM. It augments perfusion, may ameliorate the pressure gradient, and often elicits a potentially beneficial vagal reflex when used to treat tachyarrhythmia-induced hypotension.

The inhalation anesthetics commonly are used for patients with HCM. Their dose-dependent myocardial depression is ideal because negative inotropy reduces the degree of SAM-septal contact, which reduces LVOT obstruction. Hypotension is usually the result of underlying hypovolemia, which is potentially exacerbated by anesthetic-induced vasodilation. Inotropes, β-adrenergic agonists, and calcium are contraindicated because they worsen the systolic obstruction and perpetuate the hypotension. In most cases, a beneficial response can be obtained with aggressive replenishment of intravascular volume and concurrent infusion of phenylephrine.

Aortic Regurgitation

You're Reading a Preview

Become a Clinical Tree membership for Full access and enjoy Unlimited articles

Become membership

If you are a member. Log in here